Recent Posts
- Ukraine recovery should be based on development of territorial communities, innovations, involvement of professional domestic community – results of ESUR forum 29.06.2023
- Ukraine repatriates five more seriously wounded Russian POWs 10.04.2023
- Rada intends to include history of Ukraine, foreign language in final certification for general secondary education 10.04.2023
- Rada terminates protocol on joint anti-terrorist measures in CIS territories for Ukraine 10.04.2023
- 100 Ukrainians, incl defenders of Mariupol, returned according to swap procedure – Yermak 10.04.2023
Due to presence of Russia-based production, not single foreign pharma company-supplier of centralized medical purchases lost its marketing authorization
KYIV. Jan 16 (Interfax-Ukraine) – Not a single foreign pharmaceutical company, which is a supplier of medicines purchased at the expense of the national budget, has lost its marketing authorization due to the presence of manufacturing sites in Russia, Deputy Director General of the State Enterprise "Medical Procurement of Ukraine" Edem Adamanov said.
"Fortunately, so far there is not a single company from our centralized nomenclature that would have had its marketing authorization taken away due to the presence of manufacturing sites in the Russian Federation or Belarus," he said.
At the same time, according to Adamanov, "there are some companies at risk."
"If their marketing authorization is taken away from them, their goods will cost more. But there is no critical situation for any pharma company capable of delivering it," he said.
Adamanov said at the present time "one or two companies" may lose their marketing authorization due to production.
